Artwork

Content provided by spacinsider. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by spacinsider or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Tim Moran of Avertix, and Ross Haghighat of BioPlus Acquisition Corp.

40:17
 
Share
 

Manage episode 377051590 series 2985779
Content provided by spacinsider. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by spacinsider or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Biotech firms tend to come on to SPACs’ radar when they still have some clinical work to complete to get to an approved medicine or device, but Avertix is ahead of that particular curve.

This week, we speak with Tim Moran, President and CEO of Avertix, and Ross Haghighat, CEO and CFO of BioPlus Acquisition Corp. (Nasdaq: BIOS). The two announced a $195 million dollar combination in May of this year.

Tim tells us how Avertix’s Guardian heart monitoring implant has performed in its initial commercial rollout, having already been approved by the FDA and for insurance reimbursements.

Ross meanwhile explains why being at that stage of the process was important for BioPlus’ criteria given the current market conditions and what further value streams could be unlocked by the Guardian device long term.

  continue reading

100 episodes

Artwork
iconShare
 
Manage episode 377051590 series 2985779
Content provided by spacinsider. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by spacinsider or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Biotech firms tend to come on to SPACs’ radar when they still have some clinical work to complete to get to an approved medicine or device, but Avertix is ahead of that particular curve.

This week, we speak with Tim Moran, President and CEO of Avertix, and Ross Haghighat, CEO and CFO of BioPlus Acquisition Corp. (Nasdaq: BIOS). The two announced a $195 million dollar combination in May of this year.

Tim tells us how Avertix’s Guardian heart monitoring implant has performed in its initial commercial rollout, having already been approved by the FDA and for insurance reimbursements.

Ross meanwhile explains why being at that stage of the process was important for BioPlus’ criteria given the current market conditions and what further value streams could be unlocked by the Guardian device long term.

  continue reading

100 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide